Enorama Pharma AB (publ) (STO:ERMA)
Sweden · Delayed Price · Currency is SEK 1.240
+0.848 (216.33%)
Aug 14, 2026, 5:29 PM CET
Enorama Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 17.76 | 3.04 | 2.09 | 6.15 | 4.14 | 12.2 |
Cash & Short-Term Investments | 17.76 | 3.04 | 2.09 | 6.15 | 4.14 | 12.2 |
Cash Growth | 282.14% | 45.66% | -66.11% | 48.66% | -66.07% | 157.71% |
Accounts Receivable | 1.06 | 1.72 | 0.21 | 0.02 | 1.95 | 7.06 |
Other Receivables | 0.49 | 0.93 | 1.2 | 2.03 | 2.37 | 1.45 |
Receivables | 1.55 | 2.65 | 1.41 | 2.05 | 4.32 | 8.5 |
Inventory | 1.87 | 1.75 | 11.28 | 4.29 | 2.84 | 1.24 |
Prepaid Expenses | 1.59 | 0.56 | 0.39 | 0.47 | 0.45 | 0.47 |
Other Current Assets | -0 | -0 | - | - | - | - |
Total Current Assets | 22.77 | 8 | 15.16 | 12.96 | 11.75 | 22.41 |
Property, Plant & Equipment | 0.01 | 0.01 | 0.14 | 0.86 | 1.54 | 2.22 |
Long-Term Deferred Charges | 0.17 | 0.25 | 0.59 | 20.56 | 23.43 | 26.3 |
Other Long-Term Assets | - | -0 | - | - | 12 | - |
Total Assets | 22.95 | 8.26 | 15.89 | 34.39 | 48.72 | 50.93 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 5.68 | 6.5 | 1.17 | 3.72 | 5.35 | 2.18 |
Accrued Expenses | 3.25 | 2.81 | 1.5 | 4.02 | 2.04 | 2.24 |
Current Portion of Long-Term Debt | - | - | - | 0.13 | 1.46 | 2.09 |
Current Income Taxes Payable | - | - | - | 0.29 | 0.43 | 0.39 |
Other Current Liabilities | 26.44 | 22.41 | 5.43 | 2.06 | 3.14 | 4.79 |
Total Current Liabilities | 35.37 | 31.71 | 8.09 | 10.22 | 12.43 | 11.68 |
Long-Term Debt | - | - | - | 0.3 | 0.45 | 1.7 |
Other Long-Term Liabilities | 24.21 | - | - | 4.33 | 4.33 | 16.2 |
Total Liabilities | 59.58 | 31.71 | 8.09 | 14.85 | 17.2 | 29.58 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 11.66 | 11.66 | 9.45 | 6.39 | 1.46 | 1.2 |
Additional Paid-In Capital | 270.15 | 270.15 | 237.99 | 205.32 | 176.55 | 126.45 |
Retained Earnings | -318.44 | -305.25 | -239.64 | -192.18 | -149.07 | -106.29 |
Comprehensive Income & Other | - | - | - | - | 2.58 | - |
Shareholders' Equity | -36.64 | -23.45 | 7.8 | 19.54 | 31.52 | 21.35 |
Total Liabilities & Equity | 22.95 | 8.26 | 15.89 | 34.39 | 48.72 | 50.93 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | 0.44 | 1.91 | 3.79 |
Net Cash (Debt) | 17.76 | 3.04 | 2.09 | 5.72 | 2.23 | 8.41 |
Net Cash Growth | 282.14% | 45.66% | -63.53% | 156.37% | -73.49% | - |
Net Cash Per Share | 0.24 | 0.04 | 0.04 | 0.21 | 0.28 | 1.36 |
Filing Date Shares Outstanding | 74.59 | 74.59 | 60.47 | 40.93 | 25.86 | 7.69 |
Total Common Shares Outstanding | 74.59 | 74.59 | 60.47 | 40.93 | 9.35 | 7.69 |
Working Capital | -12.6 | -23.72 | 7.07 | 2.75 | -0.67 | 10.73 |
Book Value Per Share | -0.49 | -0.31 | 0.13 | 0.48 | 3.37 | 2.78 |
Tangible Book Value | -36.64 | -23.45 | 7.8 | 19.54 | 31.52 | 21.35 |
Tangible Book Value Per Share | -0.49 | -0.31 | 0.13 | 0.48 | 3.37 | 2.78 |
Machinery | - | 2.12 | 2.15 | 3.37 | 3.37 | 3.37 |